NYSE:GMED Globus Medical (GMED) Stock Forecast, Price & News $49.96 +0.46 (+0.93%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$49.09▼$50.1350-Day Range$49.10▼$62.3152-Week Range$48.86▼$80.04Volume1.65 million shsAverage Volume1.46 million shsMarket Capitalization$5.02 billionP/E Ratio24.86Dividend YieldN/APrice Target$68.22 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Globus Medical MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside36.6% Upside$68.22 Price TargetShort InterestHealthy4.29% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.97Based on 12 Articles This WeekInsider TradingN/AProj. Earnings Growth10.82%From $2.31 to $2.56 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.06 out of 5 starsMedical Sector34th out of 976 stocksSurgical & Medical Instruments Industry6th out of 100 stocks 3.1 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.22, Globus Medical has a forecasted upside of 36.6% from its current price of $49.96.Amount of Analyst CoverageGlobus Medical has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.29% of the outstanding shares of Globus Medical have been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Globus Medical has recently decreased by 59.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 3.9 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Globus Medical this week, compared to 4 articles on an average week.Search Interest3 people have searched for GMED on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have not sold or bought any company stock.Percentage Held by Insiders24.30% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.54% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 10.82% in the coming year, from $2.31 to $2.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 24.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 24.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.08.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Globus Medical (NYSE:GMED) StockGlobus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Read More GMED Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMED Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comGlobus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 23, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for Globus Medical, Inc. (NYSE:GMED) Boosted by AnalystSeptember 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 22, 2023 | americanbankingnews.comFY2023 EPS Estimates for Globus Medical, Inc. Increased by Zacks Research (NYSE:GMED)September 19, 2023 | msn.comStifel Upgrades Globus Medical Inc - (GMED)September 19, 2023 | markets.businessinsider.comGlobus Medical's Untapped Potential Beyond The NUVA Transaction; Analyst Turns BullishSeptember 19, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Lifted to Buy at Stifel NicolausSeptember 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Align Tech (ALGN) and Globus Medical (GMED)September 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 17, 2023 | americanbankingnews.comWells Fargo & Company Trims Globus Medical (NYSE:GMED) Target Price to $58.00September 17, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Price Target Cut to $58.00September 13, 2023 | seekingalpha.comGlobus Medical: Almost Having My BackSeptember 8, 2023 | finance.yahoo.comGlobus Medical (GMED) Launches NuVasive's NSO in Global MarketSeptember 7, 2023 | finance.yahoo.comNuVasive Specialized Orthopedics Launches Precice Bone Transport in International MarketsSeptember 6, 2023 | nasdaq.comTruist Securities Reiterates Globus Medical Inc - (GMED) Hold RecommendationSeptember 5, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Globus MedicalSeptember 1, 2023 | bizjournals.comDone deal: Globus Medical, NuVasive complete $3B mergerAugust 28, 2023 | msn.comJackson financial, Goosehead Insurance to join S&P SmallCap 600August 18, 2023 | msn.comNuVasive/Globus deal spread narrows amid report on optimism for regulatory approvalAugust 8, 2023 | msn.comBarclays Maintains Globus Medical Inc - (GMED) Overweight RecommendationAugust 8, 2023 | msn.comGlobus Medical: Slightly Too Pricey Right NowAugust 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cellectis SA (CLLS), Globus Medical (GMED) and Blueprint Medicines (BPMC)August 6, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Hold Rating for Globus Medical (GMED)August 5, 2023 | msn.comWells Fargo Maintains Globus Medical Inc - (GMED) Equal-Weight RecommendationAugust 5, 2023 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on Globus Medical (GMED)August 3, 2023 | msn.comHere's What Key Metrics Tell Us About Globus Medical (GMED) Q2 EarningsSee More Headlines Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Company Calendar Last Earnings8/03/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$68.22 High Stock Price Forecast$78.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+38.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$2.01 Trailing P/E Ratio24.52 Forward P/E Ratio21.34 P/E Growth1.89Net Income$190.17 million Net Margins18.63% Pretax Margin23.83% Return on Equity12.13% Return on Assets10.83% Debt Debt-to-Equity RatioN/A Current Ratio7.80 Quick Ratio5.63 Sales & Book Value Annual Sales$759.12 million Price / Sales6.52 Cash Flow$2.79 per share Price / Cash Flow17.66 Book Value$18.43 per share Price / Book2.67Miscellaneous Outstanding Shares100,460,000Free Float76,049,000Market Cap$4.95 billion OptionableOptionable Beta1.08 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David C. Paul (Age 56)Co-Founder & Exec. Chairman Comp: $1.09MMr. Daniel T. Scavilla (Age 58)Pres, CEO & Director Comp: $1.37MMr. Keith W. Pfeil (Age 44)Sr. VP & CFO Comp: $675.89kMs. Kelly G. Huller Esq. (Age 51)Sr. VP, Gen. Counsel & Sec. Comp: $543.24kMr. Brian J. Kearns (Age 56)Sr. VP of Bus. Devel. & Investor Relations Key CompetitorsIntegra LifeSciencesNASDAQ:IARTAtriCureNASDAQ:ATRCAlphatecNASDAQ:ATECTeleflexNYSE:TFXInsuletNASDAQ:PODDView All CompetitorsInsiders & InstitutionsBarclays PLCSold 815,912 shares on 9/21/2023Ownership: 0.395%Davidson Kempner Capital Management LPBought 268,860 shares on 9/12/2023Ownership: 0.476%Virginia Retirement Systems ET ALBought 48,800 shares on 8/22/2023Ownership: 0.049%Comerica BankBought 18,917 shares on 8/22/2023Ownership: 0.019%Osaic Holdings Inc.Sold 1,127 shares on 8/21/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions GMED Stock - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price forecast for 2023? 12 brokerages have issued twelve-month price objectives for Globus Medical's stock. Their GMED share price forecasts range from $58.00 to $78.00. On average, they anticipate the company's stock price to reach $68.22 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2023? Globus Medical's stock was trading at $74.27 at the beginning of the year. Since then, GMED shares have decreased by 33.6% and is now trading at $49.29. View the best growth stocks for 2023 here. Are investors shorting Globus Medical? Globus Medical saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 4,310,000 shares, a decrease of 59.2% from the August 31st total of 10,570,000 shares. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is currently 2.6 days. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its earnings results on Thursday, August, 3rd. The medical device company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.03. The medical device company earned $291.62 million during the quarter, compared to analyst estimates of $279.54 million. Globus Medical had a trailing twelve-month return on equity of 12.13% and a net margin of 18.63%. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.56 EPS. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE) and First Trust Health Care AlphaDEX Fund (FXH).iShares U.S. Medical Devices ETF (IHI). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $2.30-$2.30 for the period, compared to the consensus earnings per share estimate of $2.30. The company issued revenue guidance of $1.13 billion-$1.13 billion, compared to the consensus revenue estimate of $1.12 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." Who are Globus Medical's major shareholders? Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.33%), State Street Corp (2.36%), William Blair Investment Management LLC (2.27%), JPMorgan Chase & Co. (1.89%), Champlain Investment Partners LLC (1.70%) and Hawk Ridge Capital Management LP (1.68%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil and Kelly Huller. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $49.29. How much money does Globus Medical make? Globus Medical (NYSE:GMED) has a market capitalization of $4.95 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $2.01 on an earnings per share basis. How many employees does Globus Medical have? The company employs 2,600 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042. This page (NYSE:GMED) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.